Eleftherios P. Diamandis

ORCID: 0000-0002-1589-820X · 10 papers in corpus
preprint 2018
·doi:10.12688/f1000research.13863.1

Background: To elucidate potential markers of endometriosis and endometriosis-associated endometrioid and clear cell ovarian carcinomas using mass spectrometry-based proteomics. Methods: A total of 21 fresh, frozen tissues from patients …

preprint 2018
F1000Research ·doi:10.12688/f1000research.13863.2

Background: To elucidate potential markers of endometriosis and endometriosis-associated endometrioid and clear cell ovarian carcinomas using mass spectrometry-based proteomics. Methods: A total of 21 fresh, frozen tissues from patients dia…

2017
BMC medicine ·doi:10.1186/s12916-017-0817-5

BackgroundTEX101 is a cell membrane protein exclusively expressed by testicular germ cells and shed into seminal plasma. We previously verified human TEX101 as a biomarker for the differential diagnosis of azoospermia, and developed a first…

article 2016
·doi:10.1158/1557-3265.ovca15-b13

Abstract Introduction and Objectives: It is evident that ovarian cancer (OvCa) is not a single disease but is made up of several distinct subtypes, including serous, endometrioid, clear cell and mucinous. The gold-standard biomarker CA125 p…

2013
Clinical chemistry ·doi:10.1373/clinchem.2012.187047
2012
Clinical biochemistry ·doi:10.1016/j.clinbiochem.2012.08.011

ObjectivesTo measure the levels of serum CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in patients with ovarian cancer (OvCa), benign gynecological conditions and healthy women and in a number of other cancer types (breast…

2010
Clinical biochemistry ·doi:10.1016/j.clinbiochem.2009.10.012

ObjectivesNew ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes.Design and methodsNidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 w…

2009
Molecular & cellular proteomics : MCP ·doi:10.1074/mcp.m800313-mcp200

Current ovarian cancer biomarkers are inadequate because of their relatively low diagnostic sensitivity and specificity. There is a need to discover and validate novel ovarian cancer biomarkers that are suitable for early diagnosis, monitor…

2008
British journal of cancer ·doi:10.1038/sj.bjc.6604630

Currently, there are no effective biomarkers for ovarian cancer prognosis or prediction of therapeutic response. The objective of this study was to examine a panel of 10 serum biochemical parameters for their ability to predict response to …

2007
British journal of cancer ·doi:10.1038/sj.bjc.6603556

The human tissue kallikrein family (KLK for protein; KLK for gene) includes 15 members. Twelve kallikreins, including KLK6, are concurrently upregulated in ovarian cancer. However, the mechanism of this phenomenon remains unclear. In this s…